Abstract |
From 1964 to 1979, 57 children with acute myelocytic leukemia have been treated at the University Children's Hospital, Zürich. The overall remission rate was 0.60, with a median remission duration of 2 months and survival of 6.4 months. Patients with FAB type M 1 responded best, but longtime survivors were observed from all FAB types. Whereas in the 1960s only 4/19 achieved (short) remission, now, since the introduction of cytosine arabinoside, remissions are observed on 79% but median survival (10 months) is still short compared with acute lymphocytic leukemia. However, 11/38 children treated since 1971 survived for more than 2 years. Four of these relapsed (after less than 23 months of complete remission), while of the remaining seven, 5 have been off treatment for 5 to 77 months. This group includes children of both sexes, all ages, low and high WBS's, with organ infiltrates (excluding CNS and skin), and in whom the time taken to achieve M 1 marrow played no role. These results show that, with combination chemotherapy including cytosin arabinoside, remission can almost always be attained, but prolonged remission can be maintained only in about 1/5 of these children. The problems of maintenance treatment and CNS-prophylaxis need more attention in the future.
|
Authors | H J Plüss, W H Hitzig |
Journal | Schweizerische medizinische Wochenschrift
(Schweiz Med Wochenschr)
Vol. 110
Issue 40
Pg. 1459-62
(Oct 04 1980)
ISSN: 0036-7672 [Print] Switzerland |
Vernacular Title | Die akuten myeloischen Leukämien im Kindesalter: Behandlungsresultate 1964--1979. |
PMID | 6944786
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Cytarabine
(therapeutic use)
- Female
- Humans
- Infant
- Leukemia, Myeloid
(drug therapy)
- Male
|